|Awarded On||May 18, 2016|
|Title||Development of high throughput technology to identify drugs for muscle wasting during cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas Tech University|
|Principal Investigator/Program Director||Siva Vanapalli|
|Cancer Sites||Colorectal, Lung and Bronchus, Pancreas, Small Intestine|
A significant number of cancer patients experience muscle wasting, a phenomenon that is clinically referred to as cachexia. Due to a substantial loss in muscle mass and strength, cachexia presents a major quality of life problem for cancer patients. Cachexia patients suffer from fatigue, fitness loss, lethargy, psychological burden, and have difficulty battling the side effects of chemotherapy. Increased feeding does not improve muscle mass and strength due to accelerated degradation of muscle proteins. Importantly, one-third of the cancer deaths are attributed to cachexia and there are no approved drugs for its treatment. In this proposal, we seek to develop a high throughput technology for...